TScan Therapeutics (TCRX) director granted stock options on 67,000 shares

Rhea-AI Filing Summary

TScan Therapeutics director Barbara Klencke received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. The entire grant will vest and become exercisable upon the earlier of May 20, 2027 or the company’s next annual stockholder meeting, provided she continues serving the company through that date. Following this grant, she holds options on 67,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Klencke Barbara

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	67,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 67,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 67,000 shares Exercise price: $0.9946 per share Underlying shares: 67,000 shares +3 more

6 metrics

Option grant size 67,000 shares Stock Option (Right to Buy) granted to director

Exercise price $0.9946 per share Stock option exercise price for Voting Common Stock

Underlying shares 67,000 shares Voting Common Stock underlying the option

Total options after grant 67,000 shares Total shares subject to options following transaction

Option expiration May 20, 2036 Expiration date of the stock option grant

Vesting date trigger May 20, 2027 or next annual meeting Options vest on earlier of these dates with continued service

Key Terms

Stock Option (Right to Buy), Voting Common Stock, exercise price, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Voting Common Stock financial

"underlying_security_title: Voting Common Stock"

exercise price financial

"conversion_or_exercise_price: 0.9946"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full"

annual meeting of the Issuer's stockholders regulatory

"the next annual meeting of the Issuer's stockholders"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klencke Barbara

(Last) (First) (Middle)

C/O TSCAN THERAPEUTICS, INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TScan Therapeutics, Inc. [ TCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9946	05/20/2026		A		67,000		(1)	05/20/2036	Voting Common Stock	67,000	$0.00	67,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Zoran Zdraveski, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did TScan Therapeutics (TCRX) report in this Form 4 for Barbara Klencke?

TScan Therapeutics reported that director Barbara Klencke received a stock option grant for 67,000 shares. These options give her the right to buy Voting Common Stock at a fixed exercise price, subject to future vesting conditions and an expiration date in 2036.

How many TScan Therapeutics (TCRX) shares are covered by Barbara Klencke’s new option grant?

The new stock option grant covers 67,000 shares of TScan Therapeutics Voting Common Stock. This entire amount reflects her total option holdings after the transaction, giving her potential future ownership if she chooses to exercise once the options vest.

What is the exercise price of Barbara Klencke’s stock options in TScan Therapeutics (TCRX)?

The stock options granted to Barbara Klencke have an exercise price of $0.9946 per share. This is the fixed price at which she may buy TScan Therapeutics Voting Common Stock if she exercises the options after they vest and before they expire.

When do Barbara Klencke’s TScan Therapeutics (TCRX) stock options vest?

The options will vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of TScan Therapeutics’ stockholders. Vesting is conditioned on her continued service with the company through the applicable vesting date.

What is the expiration date of Barbara Klencke’s TScan Therapeutics (TCRX) option grant?

Barbara Klencke’s stock options expire on May 20, 2036. After this expiration date, any unexercised portion of the 67,000-share grant will lapse, meaning she will no longer have the right to purchase shares under this specific option award.

Is Barbara Klencke’s TScan Therapeutics (TCRX) Form 4 transaction a market buy or sell?

This Form 4 reflects a grant of stock options, not a market purchase or sale. The transaction is classified as an acquisition of a derivative security as compensation, so no open-market trading price or sale proceeds are involved at this stage.